Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinclus Pharma in connection with a private placement
Mandate

Vinge advises Cinclus Pharma in connection with a private placement

May 20, 2022 Intellectual Property Capital Markets and Public M&A Corporate Tax

Vinge has advised the biopharmaceutical development company Cinclus Pharma in connection with a private placement of approximately SEK 240 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of linaprazan glurate, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD), accelerate the Company’s commercialization strategy and broaden the shareholder base.

Vinge’s team consisted primarily of Dain Hård Nevonen, Amanda Knutsson, Stojan Arnerstål, Maria Schultzberg and Anna Svensson.

Related

Vinge has advised Gränges on the refinancing of its sustainability-linked credit facility

 Vinge has advised Gränges AB (publ) (“Gränges”), a global leader in aluminium rolling and recycling in selected niches, on the refinancing of its sustainability-linked credit facility, which supports Gränges’ sustainability plan.
February 10, 2025

Vinge has advised Priveq Fund VII in connection with a sustainability-linked credit facility

 Priveq Fund VII has entered into a credit facility agreement with Swedbank AB (publ) which will primarily be used to finance the fund’s investment activities. The credit facility is linked to certain of Priveq’s sustainability targets, which means that the interest rate on the credit facility will be adjusted up or down based on the performance of Priveq Fund VII's portfolio companies.
February 10, 2025

Vinge advised ReCarber in financing round

 Vinge has advised ReCarber AB in its SEK 60 million financing round. The investors included Luminar Ventures, Spintop Ventures and Course Corrected.
February 10, 2025